Articles

TriGuard, Keystone, embolic protection, TAVR

March 19, 2015 — An investigational device that deflects debris away from the brain during transcatheter aortic valve replacement (TAVR) seems to improve in-hospital safety outcomes and cognitive...

Sterne Agee, ACC, Medtronic, Edwards, St. Jude, TAVR, heart failure

The American College of Cardiology (ACC) hosted its 64th Annual Scientific Session & Expo over the weekend in San Diego, California. Key data from multiple transcatheter aortic valve...

CoreValve, high risk study, TAVR, Medtronic, ACC

Medtronic plc unveiled new two-year data from the CoreValve U.S. Pivotal High Risk Study, which demonstrated superior two-year survival benefits from transcatheter aortic valve replacement (TAVR)...

Edwards, Sapien, PARTNER trial, five-year outcomes, ACC

Five-year data suggest that the Sapien transcatheter heart valve (Edwards Lifesciences) is a feasible option for patients with severe aortic stenosis deemed to be at high risk for open-heart...

St. Jude, CardioMEMS, CHAMPION trial, heart failure, reduced ejection fraction

Heart failure patients with reduced ejection fraction experienced significant HF mortality and hospitalization reductions via guideline-directed medical therapy managed by pulmonary artery...

Minneapolis Heart Institute Foundation, PCI, STEMI, late presenters

New research from the Minneapolis Heart Institute Foundation (MHIF) finds that percutaneous coronary intervention for heart attacks can still be beneficial for patients who get to their more than...

Computed tomography, coronary CT angiography, PROMISE trial, ACC

Results from the PROMISE clinical trial confirmed what many cardiologists and radiologists have long suspected to be true: Coronary computed tomographic angiography (coronary CTA) is...

Medtronic, Drug Filled Stent, clinical trial, ACC

Medtronic plc unveiled the preclinical outcomes of its novel Drug-Filled Stent (DFS) at the 64th Annual Scientific Session of the American College of Cardiology (ACC). The preclinical data showed...

Boston Scientific, Watchman LAA device, FDA approval

Boston Scientific Corp. has received U.S. Food and Drug Administration (FDA) approval for the Watchman left atrial appendage closure device. The Watchman device offers a new stroke risk reduction...

UTHealth, telemedicine, acute stroke, telestroke

For the first time, researchers at The University of Texas Health Science Center at Houston (UTHealth) were able to enroll patients at other hospitals into an acute stroke clinical trial.